BerlinAnalytix‘s expertise is focussed on the following areas:
BerlinAnalytix provides comprehensive support for biomaterial studies.
Our scientists are engaged in research and development in the fields of Energy, Chemistry and Diagnostics. The emphasis is on hydrogen-based energy supply, sustainable chemistry, and process analysis as well as personalized diagnostics and liquid biopsy.
In the division Analysis Systems and Sensors, we create efficient solutions for the extraction and enrichment of relevant biomarkers and cells for fast, automated, and personalized precision diagnostics in the laboratory and also on-site. With our development work we achieve an essential contribution to the societal challenges “secure, clean and efficient energy”, “climate action, environment and resource efficiency” as well as “health”.
The Fraunhofer Institute for Laser Technology ILT is worldwide one of the most important development and contract research institutes of its specific field. The activities cover a wide range of areas including e.g. laser cutting, drilling, welding and soldering as well as surface treatment, micro processing and additive manufacturing.
The technology field Medical Technology and Biophotonics develops applications for lasers in Bioprinting, therapy and diagnostics. Bioprinting technologies are investigated for cell identification and single cell printing. Using nanostructuring and photochemical surface modification, the field is making a contribution to generating biofunctional surfaces.
Since its foundation in 2001, ibidi GmbH has developed an extensive product range in the field of cell-based assays. The company has a large technology portfolio for the necessary microfluidic microscopy slides made of optically high-quality plastics. The carriers are designed in our own research and development department using 3D-CAD solutions.
Design, production, rapid prototyping, surface treatment and application tests take place in our own facilities and laboratories. ibidi has 25 families of intellectual property rights with over 80 actively pursued individual applications of which 60 patents have been granted. The company is certified according to ISO 9001 and ISO 13485.
Liquid handling, spotting, and automated dispensing of liquid amounts in the sub-microliter range is an essential step in the production of biochips, lateral flow or lab-on-a-chip devices. The printing of microarrays and the fabrication of biosensors all require a precise and reliable handling of very small amounts of fluids.
Microdrop Technologies provides a variety of non-contact micro-dispensing products ideally suited for this demanding application field. High-precision dispensing of volumes in the picoliter and nanoliter range enables the user to print spots or lines and structures of aqueous solutions as well as solvent-based liquids in a wide viscosity range.
myriamed’s aim is to contribute to the development of new cures for today’s most debilitating diseases by defining wanted and unwanted drug effects at the earliest possible time point.
Founded in 2012 by experts in cell and engineered muscle models myriamed is determined to provide our customers with standardized and individualized solutions to move preclinical drug development closer to clinical reality.
The proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. myriamed’s screening platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
For clients in the medical technology and biomedicine fields, we conduct R&D studies and offer a suite of services. The focus of the Group Regenerative Biomaterials is on:
PRIMACYT offers one of the world’s most comprehensive portfolios of liver related products obtained from human and animal species like birds, fresh and seawater fish, rodents, and farm animals. We offer primary human and animal cells, liver subcellular fractions, ex vivo skin explants, and consumables for applications in environmental toxicology, preclinical testing and product development in human and animal health. Products are manufactured in accordance with OECD test guidelines.
We have a validated technology platform to assay drug transporter activities in stably transfected HEK293-cells and primary hepatocytes. We are GLP certified and serve as a reference laboratory for the EU.
BioCity was founded in 2002 when the concept of a business incubator offering 360° support within a self-contained campus was unheard of. But a small team of dedicated people fought hard to turn that great idea into reality, a reality now replicated throughout the UK. But we’re not finished yet.
Not limited to the standard ‘business incubator’ model, the ever-growing team at BioCity work tirelessly for the companies who call us home and the industry we are proud to be a part of.
Biogelx hydrogel technology is based on simple peptides (2-3 aa) that self-assemble into fibres in aqueous environments. Our hydrogels and bioinks are non-animal derived, they are reproducible and consistent, with no batch to batch variation.
Our gels offer tunable mechanical properties over a wide range of stiffness, (from 0.5 and up to 100 kPa) to allow optimization of the final gel depending on the specific cell/tissue type and application. Additionally, the hydrogels and bioinks are ‘biochemically tunable’; we also provide gels/inks incorporating RGD (fibronectin), GFOGER (collagen) and other biomimetic peptide sequences.
Jellagen® Limited is an ISO13485:2016 certified marine biotechnologies company GMP- manufacturing of high value purified marine collagen extracted from a specific jellyfish. Jellagen’s marine collagen technology is supplied into the cell culture market and technology platform is also utilised to develop innovative tissue engineering solutions.
The product range includes:
JellaGel™ - 3D collagen hydrogels suitable for 3D cell culture and bioprinting platform
Poietis is an innovative biotechnology company that developed NGB-R, a 4th-generation multi-modal biofabrication instrument featuring exclusive bioprinting technologies and industrial-grade robotics for reproducible, operator-independent processes.
With over 52 exclusive patents filed, Poietis is the only company that offers laser-assisted bioprinting (LAB) technology. With LAB, cells can be spatially organized into a specific pattern, positioned in 3D with extremely high cellular resolution and printed with superior cellular viability (>95%).
Over the past few years, Poietis partnered up with some of the world’s leading cosmetics and pharmaceutical groups such as L’Oréal, Servier and BASF.